{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"49.1","value":"34.8"}]}],"title":"TTP for all evaluable patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"49.1","value":"38.7"}]}],"title":"TTP for responding patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"45.8","value":"15.25"}]}],"title":"TTP for previously treated patients"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"49.1","value":"36.04"}]}],"title":"TTP for previously untreated patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Time to disease progression (TTP) was calculated from the start of therapy using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks\n\nRituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.\n\nThalidomide: 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.\n\nRituximab: Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.","id":"OG000","title":"Thalidomide and Rituximab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"49.1 months","title":"Time to Progression","type":"PRIMARY","unitOfMeasure":"months"}